Literature DB >> 32038924

The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer.

Carme Obiols1, Sergi Call1,2, Ramon Rami-Porta1,3.   

Abstract

Entities:  

Year:  2019        PMID： 32038924      PMCID： PMC6987341          DOI： 10.21037/tlcr.2019.07.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients.

Authors:  Terumoto Koike; Teruaki Koike; Yasushi Yamato; Katsuo Yoshiya; Shin-Ichi Toyabe
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

2.  Report from the European Society of Thoracic Surgeons Database 2017: patterns of care and perioperative outcomes of surgery for malignant lung neoplasm.

Authors:  Michele Salati; Alessandro Brunelli; Herbert Decaluwe; Zalan Szanto; Marcel Dahan; Gonzalo Varela; Pierre-Emmanuel Falcoz
Journal:  Eur J Cardiothorac Surg       Date:  2017-12-01       Impact factor: 4.191

3.  Prediction Model for Nodal Disease Among Patients With Non-Small Cell Lung Cancer.

Authors:  Francys C Verdial; David K Madtes; Billanna Hwang; Michael S Mulligan; Katherine Odem-Davis; Rachel Waworuntu; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2019-01-30       Impact factor: 4.330

4.  [Risk factors in bronchogenic carcinoma surgery].

Authors:  José Luis Duque; Ramón Rami-Porta; Ana Almaraz; Manuel Castanedo; Jorge Freixinet; Antonio Fernández de Rota; Angel López Encuentra
Journal:  Arch Bronconeumol       Date:  2007-03       Impact factor: 4.872

5.  Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study.

Authors:  Herbert Decaluwé; Christophe Dooms; Xavier Benoit D'Journo; Sergi Call; David Sanchez; Benedikt Haager; Roel Beelen; Volkan Kara; Thomas Klikovits; Clemens Aigner; Kurt Tournoy; Mahmood Zahin; Johnny Moons; Geoffrey Brioude; Juan Carlos Trujillo; Walter Klepetko; Akif Turna; Bernward Passlick; Laureano Molins; Ramon Rami-Porta; Pascal Thomas; Paul De Leyn
Journal:  Eur Respir J       Date:  2017-12-21       Impact factor: 16.671

6.  [Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) for staging of non-small-cell lung cancer (NSCLC)].

Authors:  Marcin Zieliński; Lukasz Hauer; Jolanta Hauer; Juliusz Pankowski; Artur Szlubowski; Tomasz Nabiałek
Journal:  Pneumonol Alergol Pol       Date:  2011

7.  Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

Authors:  Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

8.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Eur J Cardiothorac Surg       Date:  2014-02-26       Impact factor: 4.191

9.  Video-Assisted Mediastinoscopic Lymphadenectomy for Staging Non-Small Cell Lung Cancer.

Authors:  Sergi Call; Carme Obiols; Ramon Rami-Porta; Juan Carlos Trujillo-Reyes; Manuela Iglesias; Roser Saumench; Guadalupe Gonzalez-Pont; Mireia Serra-Mitjans; Jose Belda-Sanchís
Journal:  Ann Thorac Surg       Date:  2016-01-21       Impact factor: 4.330

10.  Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.

Authors:  Robert J Cerfolio; Ayesha S Bryant
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.